Status:
COMPLETED
Dalacin-T Gel Post Approval Study
Lead Sponsor:
Pfizer
Collaborating Sponsors:
Parexel
SACT INTERNATIONAL Co., LTD.
Conditions:
Acne Vulgaris
Eligibility:
All Genders
13-35 years
Phase:
PHASE4
Brief Summary
To investigate, in a comparison vs. Acuatim cream (nadifloxacin cream), the efficacy and safety of Dalacin T Gel (clindamycin phosphate gel) as a therapeutic medication for acne vulgaris in acne vulga...
Eligibility Criteria
Inclusion
- Acne vulgaris patients found by a investigator to have at least 10 inflammatory lesions (papules, pustules) on a portion of either a cheeks or the forehead, with an inflammation severity of moderate or worse.
Exclusion
- Patients with, for example, acne elastosis, steroidal acne, necrotizing acne, or occupational acne.
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2005
Estimated Enrollment :
134 Patients enrolled
Trial Details
Trial ID
NCT00219570
Start Date
January 1 2005
End Date
June 1 2005
Last Update
May 11 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.